- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01471977
Treatment Adherence of Tuberculosis Medicines (TBAD)
November 15, 2011 updated by: Maliha Naseer, Gambat Institute of Medical Sciences
Interventions to Promote Adherence to Tuberculosis Treatment Among Patients Attending Basic Medical Unit of Taluka Gambat, Pakistan
It was hypothesized that tuberculosis patients receiving multiple interventions like educations, counseling and default tracing along with DOTS were more likely to adhere to tuberculosis treatment as compared to few interventions or DOTS only.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
1280
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sindh
-
Khairpur, Sindh, Pakistan
- Basic Medical Unit of Taluka Gambat
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- adult patient
- > 18years
- either sex
- diagnosed to have tuberculosis through chest x ray or sputum microscopy
- eligible to participate in the study
Exclusion Criteria:
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: education, counselling, default tracer
|
these interventions were administered along with standard treatment i.e.
DOTS at the time of standard follow up of patients at clinic
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Proportion of patients cured
Time Frame: 8 months
|
Cured: If the patient was sputum smear positive (ss+ve) at the time of enrollment, completed treatment, Had negative smear on 2 occasions during follow-up
|
8 months
|
|
Proportion of patients completed treatment
Time Frame: 8 months
|
Treatment completed: SS+ve, or SS-ve or extra-pulmonary, had a negative smear result at the end of intensive phase but no smear result at the end of treatment completed 8 month treatment
|
8 months
|
|
Proportion of patients died
Time Frame: 8 months
|
died during the course of treatment
|
8 months
|
|
proportion of patients defaulted
Time Frame: 8 months
|
not collected drugs for more than 2 consecutive months either sputum smear positive or negative
|
8 months
|
|
proportion of patients with treatment failure
Time Frame: 8 months
|
Treatment failure: SS+ve, found to be smear positive at 5th month or later or SS-ve found to be smear positive at 2nd month
|
8 months
|
|
proportion of patients transferred out
Time Frame: 8 months
|
Transferred to another TB register
|
8 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Nisar Sheikh, MBBS, GIMS
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2004
Primary Completion (ACTUAL)
December 1, 2007
Study Completion (ACTUAL)
February 1, 2010
Study Registration Dates
First Submitted
November 4, 2011
First Submitted That Met QC Criteria
November 15, 2011
First Posted (ESTIMATE)
November 16, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
November 16, 2011
Last Update Submitted That Met QC Criteria
November 15, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TB
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Beijing Chest HospitalHuashan Hospital; National Medical Center for Infectious DiseasesNot yet recruitingTuberculosis | Drug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampicin Resistant TuberculosisChina
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Shandong UniversityShandong Public Health Clinical CenterNot yet recruiting
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsCompletedTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
-
Huashan HospitalBeijing Chest HospitalActive, not recruitingDrug-resistant Tuberculosis | Pulmonary Tuberculosis | Rifampin-resistant TuberculosisChina
Clinical Trials on education,counseling, default tracers,quality of care
-
Centro Universitario Ricerca Interdipartimentale...Azienda Ospedaliera di Perugia; University of Perugia, Faculty of Medicine,...Recruiting
-
Institut für Pharmakologie und Präventive MedizinEdwards LifesciencesCompletedTranscatheter Aortic Valve Implantation (TAVI)Spain, Italy, France, Germany, Austria, Czechia, Romania
-
Johns Hopkins UniversityCatalyst FoundationCompletedAortic Valve Disease | Aortic Valve ReplacementUnited States
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); RTI International; AIDS Healthcare...Active, not recruitingHIV/AIDS | Substance Use | Mental Health Issue | Young Adult | Mobile HealthUnited States
-
Amasya UniversityHealth Institutes of TurkeyCompleted
-
Hamide SahinRecruiting
-
East Tennessee State UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Mayo ClinicCompletedQuality of Life | Advanced CancerUnited States
-
Izmir Katip Celebi UniversityMarmara UniversityActive, not recruitingPregnancy | Sexual Dysfunction | Postpartum Period | PLISSIT Model | Sexual CounsellingTurkey
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)UnknownOvarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Transitional Cell Carcinoma | Ovarian Transitional Cell Carcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditionsUnited States